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Background: Waist circumference, a metabolic syndrome (MetSy) criterion, is not routinely measured in clinical
practice making early identification of individuals with MetSy challenging. It has been argued that ratios of
commonly measured parameters such as lipids and lipoproteins may be an acceptable alternative for identifying
individuals with MetSy. The objective of our study was to explore clinical utility of lipid ratios to identify men and
women with MetSy; and to explore the association between lipid ratios and the number of MetSy components.
Methods: Men and women (N = 797) of Aboriginal, Chinese, European, and South Asian origin (35–60 years),
recruited across ranges of body mass index (BMI), with no diagnosed cardiovascular disease (CVD) or on
medications to treat CVD risk factors were assessed for anthropometrics, family history of CVD, MetSy components
(waist circumference, blood pressure, glucose, triglycerides (TG), high-density-lipoprotein-cholesterol (HDL-C)),
low-density-lipoprotein-cholesterol (LDL-C), nonHDL-C, and health-related behaviours.
Results: Mean levels of lipid ratios significantly increased with increasing number of MetSy components in men
and women (p < 0.05). After adjustment for age, ethnicity, smoking, alcohol consumption, physical activity, family
history of CVD and BMI, (and menopausal status in women), all lipid ratios were associated with the number of
MetSy components in men and women (Poisson regression, p < 0.001). Compared to the rest of the lipid ratios
(ROC curve analysis), TG/HDL-C was best able to discriminate between individuals with and without MetSy
(AUC = 0.869 (95% CI: 0.830, 0.908) men; AUC = 0.872 (95% CI: 0.832, 0.912) women). The discriminatory power of
TC/HDL-C and nonHDL-C/HDL-C to identify individuals with MetSY was the same (for both ratios, AUC = 0.793
(95% CI: 0.744, 0.842) men; 0.818 (95% CI: 0.772, 0.864) women). Additionally, LDL-C/HDL-C was a good marker for
women (AUC = 0.759 (95% CI: 0.706, 0.812)), but not for men (AUC = 0.689 (95% CI: 0.631, 0.748)). Based on a
multiethnic sample, we identified TG/HDL-C cut-off values of 1.62 in men and 1.18 in women that were best able
to discriminate between men and women with and without MetSY.
Conclusions: Our results indicate that TG/HDL-C is a superior marker to identify men and women with MetSy
compared to TC/HDL-C, LDL-C/HDL-C, and nonHDL-C/HDL-C.
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Metabolic syndrome is a cluster of metabolic abnormalities
associated with type 2 diabetes [1,2], cardiovascular mor-
bidity and mortality, and all-cause mortality [3,4]. It is
alarming that the prevalence of metabolic syndrome is high
and on the rise in both developed and developing countries
[5,6]. Early identification and treatment of individuals with
metabolic syndrome is imperative to prevent debilitating
consequences associated with its development. Regardless
of the approach for diagnosing metabolic syndrome, cen-
tral obesity, as measured by waist circumference, is one of
the main criteria for diagnosing metabolic syndrome
[7-10]. However, waist circumference is not routinely mea-
sured in primary care [11], which makes early identification
of individuals with metabolic syndrome challenging.
It has been argued that ratios of commonly measured
parameters such as lipids and lipoproteins may be an
acceptable alternative for identifying individuals with
metabolic syndrome [12-17]. Evidence shows that lipid
ratios perform better than individual lipids in predicting
cardiovascular risk [18-21]. Identifying a ratio to serve as
a quick and simple tool for identifying individuals at in-
creased cardiometabolic risk may decrease complexity of
and increase efficiency in identifying and monitoring
those at risk; especially as electronic medical records be-
come more commonplace or if useful biochemical ratios
were to be reported in routine laboratory test results.
However, research on clinical usefulness of lipid ratios to
identify individuals with metabolic syndrome is scarce
and mostly limited to specific population groups such as
Ghanian [17], Korean [14,16], Spanish [12], and Turkish
[13]. Furthermore, some of the available studies researched
limited number of ratios [13,17] or provided no cut-offs
for lipid ratios to help guide physicians in identifying
individuals at cardiometabolic risk [14,15]. Therefore,
the objective of this study was to explore the clinical
usefulness of lipid ratios to identify men and women






lipoprotein-cholesterol (nonHDL-C/HDL-C). In addition,
given that the number of metabolic syndrome components
has been shown to predict incident cardiovascular disease
(CVD) and type 2 diabetes [22], we additionally explored
the association of lipid ratios with the number of metabolic
syndrome components among men and women coming
from the ethnically diverse population.
Results
Participants were equally represented across sexes and
ethnicity. Compared to women, men had lower levels ofHDL-C and significantly higher levels of total cholesterol,
LDL-C, nonHDL-C, triglycerides, lipid ratios, glucose,
blood pressure, and waist circumference; also, alcohol
consumption was more prevalent among men than among
women (Table 1). Similarly, the average number of meta-
bolic syndrome components and prevalence of metabolic
syndrome were higher in men than in women.
Mean levels of lipid ratios were on average higher in
men than in women and significantly increased with in-
creasing number of metabolic syndrome components in
both men and women (Figure 1, Additional file 1: Table
S1). In both men and women, mean levels of lipid ratios
in individuals with zero metabolic syndrome components
were significantly lower from their counterparts with 1 or
more metabolic syndrome components (p < 0.05). In men
and women, except for LDL-C/HDL-C ratio, there was a
significant difference between mean levels of lipid ratios
across number of metabolic syndrome components
(p < 0.05). However, in both men and women, no signifi-
cant difference was found between mean levels of LDL-C/
HDL-C of participants with 3 and those with 4/5 meta-
bolic syndrome components (p > 0.05). Furthermore, the
results of partial correlation analyses (age and ethnicity
adjusted) reveal that in both men and women, compared
to the rest of the lipid ratios, TG/HDL-C showed stronger
correlations with waist circumference, blood pressure and
blood glucose (Additional file 2: Table S2). In addition, the
results of Poisson regression analyses indicate that, after
adjustment for age, ethnicity, smoking, alcohol consump-
tion, physical activity, family history of CVD and body
mass index (BMI) (and menopausal status in women), all
lipid ratios were significantly associated with the number
of metabolic syndrome components in both men and
women (Table 2).
Using ROC curve analyses, we plotted sensitivity over
1-specificity for each of the ratios in both men and
women (Figure 2). Compared to the rest of the lipid ra-
tios, TG/HDL-C was best able to discriminate between
apparently healthy men and women with and without
metabolic syndrome (AUC = 0.869 (95% CI: 0.830, 0.908)
for men; AUC= 0.872 (95% CI: 0.832, 0.912) for women).
The discriminatory power of TC/HDL-C and nonHDL-C/
HDL-C to identify individuals with metabolic syndrome
was the same (for both ratios, AUC= 0.793 (95% CI:
0.744, 0.842) for men; 0.818 (95% CI: 0.772, 0.864) for
women). In addition, based on Hosmer and Lemeshow’s
criteria [23] LDL-C/HDL-C was an “acceptable” marker to
discriminate between women with and without metabolic
syndrome (AUC = 0.759 (95% CI: 0.706, 0.812)), however
this was not the case for men (AUC = 0.689 (95% CI:
0.631, 0.748)). In both men and women, the analysis that
tested the statistical significance of the differences be-
tween areas under the curve revealed significant difference
between areas under the curves for all the pairs of lipid
Table 1 Distribution of risk factors in men and women
Men 380 Women 417 p value
Age (years) 46.8 ± 8.7 47.5 ± 8.9 0.241
Ethnicity 0.704
Aboriginal 81 (21.3%) 98 (23.5%)
Chinese 100 (26.3%) 118 (28.3%)
European 97 (25.5%) 99 (23.7%)
South Asian 102 (26.8%) 102 (24.5%)
Current smokers 44 (11.6%) 35 (8.4%) 0.133
Current consumers of alcohol 128 (33.7%) 98 (23.5%) 0.001
Physical activity (min/week) 226 (100, 447) 208 (95, 424) 0.269
Family history of cardiovascular disease 168 (44.2%) 187 (44.8%) 0.857
Waist circumference (cm) 92.6 ± 11.2 85.1 ± 12.2 <0.001
Body mass index (kg/m2) 27.6 ± 4.3 27.3 ± 5.3 0.498
TC (mmol/L) 5.25 ± 0.97 5.23 ± 1.03 0.776
HDL-C (mmol/L) 1.13 ± 0.29 1.43 ± 0.35 <0.001
LDL-C (mmol/L) 3.30 ± 0.85 3.17 ± 0.92 0.046
TC/HDL-C 4.91 ± 1.46 3.86 ± 1.23 <0.001
LDL/HDL-C 3.07 ± 1.01 2.35 ± 0.91 <0.001
nonHDL-C 4.12 ± 0.99 3.80 ± 1.05 <0.001
nonHDL-C/HDL-C 3.81 (2.93, 4.63) 2.68 (2.01, 3.45) <0.001
TG 1.48 (0.99, 2.22) 1.17 (0.83, 1.63) <0.001
TG/HDL-C 1.34 (0.82, 2.24) 0.86 (0.54, 1.22) <0.001
Systolic BP (mmHg) 117 (110, 124) 115 (106, 126) 0.025
Diastolic BP (mmHg) 79.2 ± 9.7 75.5 ± 9.2 <0.001
Glucose (mmol/L) 5.30 (5.00, 5.60) 5.10 (4.80, 5.40) <0.001
With MetSy 119 (31.3%) 104 (24.9%) 0.045
Number of MetSy components 1.84 ± 1.40 1.63 ± 1.22 0.026
Categorical variables presented as n (%), and sex differences were explored using Chi-square test. Continuous variables presented as mean ± SD if normally
distributed or median (25%, 75%) if skewed. Sex differences explored using t-test and Mann U Whitney test for normally distributed and skewed data, respectively.
TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, TC/HDL-C – ratio of TC and HDL-C, TG – triglycerides,
TG/HDL-C – ratio of TG and HDL-C, nonHDL-C/HDL – ratio of nonHDL-C and HDL-C, LDL-C/HDL-C – ratio of LDL-C and HDL-C, MetSy – metabolic syndrome.
Gasevic et al. Lipids in Health and Disease 2014, 13:159 Page 3 of 10
http://www.lipidworld.com/content/13/1/159ratios (Figure 2). The exception is the pair of TC/HDL-C
and nonHDL-C/HDL-C for which AUCs were the same.
Lipid ratio cut-off values, with their respective sensitivities
and specificities, for identifying individuals with metabolic
syndrome are provided in Table 3.
Discussion
The purpose of this study was to explore the clinical utility
of lipid ratios to identify men and women with metabolic
syndrome. Additionally we explored the association bet-
ween lipid ratios and number of metabolic syndrome
components. Our results indicate that increases in lipid
ratios are significantly associated with increase in the
number of metabolic syndrome components in both men
and women after adjusting for age, ethnicity, smoking sta-
tus, alcohol consumption, physical activity, family history
of CVD, and BMI (and menopausal status in women).Compared to TC/HDL-C, LDL-C/HDL-C, and nonHDL-
C/HDL-C, TG/HDL-C was shown to be a better clinical
marker to discriminate between individuals with and with-
out metabolic syndrome. These results were consistent for
men and women.
The results of our study are in line with those based
on Spanish, Korean, and Japanese populations where in-
creases in lipid ratios were shown to be associated with
increase in the number of metabolic syndrome compo-
nents [12,14,15]. Our study extends the previous fin-
dings by reporting the positive association between lipid
ratios and the number of metabolic syndrome compo-
nents in a multiethnic population; this relationship per-
sisted after adjusting for ethnicity and other factors
known to be associated with metabolic syndrome.
The observed strong relationship between lipid ratios




Figure 1 Mean levels of lipid ratios across number of metabolic
syndrome components in men and women (1A, 1B, 1C and 1D).
All means adjusted for age and ethnicity and presented as mean (95%
CI). *geometric means. Bonferroni-corrected pairwise comparisons
(0 vs. 1; 0 vs. 2; 0 vs. 3; 0 vs. ≥4; 1 vs. 2; 1 vs. 3; 1 vs. ≥4; 2 vs. 3; 2 vs. ≥4;
and 3 vs. ≥4 ): Men: Except for the pair 3 vs. ≥4 for LDL-C/HDL-C, all
other pairwise comparisons of means of TC/HDL-C, TG/HDL-C,
LDL-C/HDL-C and nonHDL-C/HDL-C across the number of metabolic
syndrome components were significant at p < 0.05. Women: Except for
the pair 3 vs. ≥4, all other pairwise comparisons of means of TC/HDL-C,
TG/HDL-C, LDL-C/HDL-C and nonHDL-C/HDL-C across the number of
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identification of individuals with constellation of cardio-
metabolic abnormalities. However, the actual lipid ratio
cut-offs to guide clinicians in identifying individuals with
metabolic syndrome are rarely reported. The studies avail-
able looked at a limited number of lipid ratios and per-
tained to specific groups such as Spanish population [12]
or a population of Ghanian women [17]. We extend the
available findings by reporting lipid ratio cut-off values for
identifying men and women with metabolic syndrome.
According to our results, in both men and women,
TG/HDL-C was shown to be a better marker to identify
individuals with metabolic syndrome compared to TC/
HDL-C, LDL-C/HDL-C, and nonHDL-C/HDL-C. Based
on a multiethnic sample, we identified TG/HDL-C cut-off
values of 1.62 in men and 1.18 in women that were best
able to discriminate between men and women with and
without metabolic syndrome. These numbers were com-
parable but slightly lower than those reported by Cordero
et al. [12] who clinically assessed a large working popula-
tion of Spanish men and women and reported TG/HDL-Table 2 The association between lipid ratios and the
number of metabolic syndrome components
Men Women
Exp (B) (95% CI) Exp (B) (95% CI)
TC/HDL-C 1.262 (1.197, 1.330) 1.278 (1.204, 1.355)
ln_TG/HDL-C 1.875 (1.680, 2.092) 1.797 (1.603, 2.016)
LDL-C/HDL-C 1.236 (1.147, 1.332) 1.358 (1.243, 1.483)
ln_nonHDL-C/HDL-C 2.861 (2.258, 3.626) 2.633 (2.109, 3.286)
All Poisson regression models adjusted for age, ethnicity, smoking, alcohol
consumption, physical activity, family history of cardiovascular disease, and
BMI. Models for women additionally adjusted for menopause status. All
models significant at p < 0.001. TC/HDL-C – ratio of total cholesterol and
high-density lipoprotein cholesterol, TG/HDL-C – ratio of triglycerides and
high-density lipoprotein cholesterol, nonHDL-C/HDL – ratio of non-high-density
lipoprotein cholesterol and high-density lipoprotein cholesterol, LDL-C/HDL-C –





Figure 2 Receiver operating characteristic curves for evaluating the usefulness of lipid ratios to identify men (A) and women (B) with
metabolic syndrome. The diagonal line indicates a test with an area under the receiver operating characteristic curve of 0.5. The areas under
the curve for TC/HDL-C and nonHDL-C/HDL-C overlapped, as the discriminatory power of TC/HDL-C and nonHDL-C/HDL-C to identify individuals
with metabolic syndrome was the same. The difference between areas under the curve (p ≤ 0.01): aTG/HDL-C vs. TC/HDL-C. bTG/HDL-C vs.
nonHDL-C/HDL-C. cTG/HDL-C vs. LDL-C/HDL-C. dTC/HDL-C vs. nonHDL/HDL-C. eTC./HDL-C vs. LDL-C/HDL-C. fnonHDL-C/HDL-C vs. LDL-C/HDL-C.
TG/HDL-C: triglyceride-to-high-density-lipoprotein-cholesterol, TC/HDL-C: total cholesterol-to-high-density-lipoprotein-cholesterol, LDL-C/HDL-C:
low-density-lipoprotein-cholesterol-to-high-density-lipoprotein-cholesterol, nonHDL-C/HDL-C: non-high-density-lipoprotein-cholesterol-to-high-
density-lipoprotein-cholesterol.
Table 3 Results of receiver-operating curve analyses featuring the thresholds of lipid ratios with their respective
sensitivities and specificities for diagnosing metabolic syndrome in men and women
Men Women
Lipid ratio Criterion value (Sensitivity, specificity) Criterion value (Sensitivity, specificity)
TG/HDL-C 1.62 (84.0%, 80.1%) 1.18 (70.2%, 88.2%)
TC/HDL-C 5.05 (73.1%, 71.6%) 3.91 (81.7%, 68.7%)
LDL-C/HDL-C* 3.79 (40.2%, 88.5%) 2.53 (67.6%, 74.8%)
nonHDL-C/HDL-C 4.05 (73.1%, 71.6%) 2.91 (79.8%, 70.9%)
*According to the AUC, LDL-C/HDL-C showed to be a good marker of metabolic syndrome in women but not in men.
Gasevic et al. Lipids in Health and Disease 2014, 13:159 Page 5 of 10
http://www.lipidworld.com/content/13/1/159
Gasevic et al. Lipids in Health and Disease 2014, 13:159 Page 6 of 10
http://www.lipidworld.com/content/13/1/159C values of 2.75 and 1.65 as cut-offs for identifying men
and women with metabolic syndrome, respectively. The
observed differences in cut-offs reported in the above
mentioned study and the ones reported in this study are
most likely due to a difference in population groups
studied.
It has recently been reported that TG/HDL-C predicts
the development of CVD as effectively as the diagnosed
metabolic syndrome [24]. Similarly, TG/HDL-C was
found to predict coronary heart disease and CVD mor-
tality as well as or even better than does metabolic
syndrome in men [25]. However, the detection of an ele-
vated TG/HDL-C is not meant to replace metabolic syn-
drome diagnosis in clinical practice; and it should rather
be considered as a simple tool to quickly identify pa-
tients at increased cardiometabolic risk for whom fur-
ther risk evaluation and clinical intervention are needed
[25]. Indeed, it has recently been reported in the study
in young adults that, compared to metabolic syndrome
diagnostic, TG/HDL-C may be able to identify a greater
number of individuals at risk; however a use of a meta-
bolic syndrome diagnostics approach identifies individ-
uals with an accentuated cardiometabolic risk profile
[26]. While metabolic syndrome diagnosis may provide
more comprehensive approach to identifying present
cardiometabolic risk factors in individuals, this diagnos-
tics is challenged by the fact that waist circumference,
one of the integrative components of metabolic syn-
drome, is not commonly measured. Indeed, it has re-
cently been reported that WC is routinely measured by
only 6% of primary care physicians [11]. If translated, it
may mean that more than 90% of primary care physi-
cians would not be able to diagnose individuals with
metabolic syndrome given that one of its components is
not routinely measured. In contrast, both TG and HDL-C
are routinely measured in clinical practice, and TG/HDL-C
could be readily calculated (or provided by the laboratory)
to serve as a quick tool to identify men and women at
increased cardiometabolic risk. This approach to use
TG/HDL-C to identify individuals at risk for whom fur-
ther care is needed may reduce time and complexity for
initial diagnosis of people with constellation of cardiomet-
abolic abnormalities.
Other research groups have also proposed TG/HDL-C
as a potential, simple tool to identify patients at in-
creased risk for CVD. The evidence shows a strong as-
sociation between TG/HDL-C and insulin resistance as
measured by glucose clamp [27,28], modified insulin
suppression test [29], and homoeostasis model assess-
ment index [29,30]. This association was also found to
be independent of waist circumference [31]. Further,
others found TG/HDL-C to be an independent predictor
of future type 2 diabetes mellitus [25,32] and its related
microvascular complications [33]; coronary heart disease[34,35]; major cardiovascular events including overall
death, myocardial infarction, and unstable angina that
required revascularization [36] and those including an-
gina pectoris, myocardial infarction, myocardial revas-
cularization, and fatal or nonfatal stroke [37]; and first
coronary event irrespective of BMI [38]. The strong rela-
tionship between TG/HDL-C and CVD may be founded
in the atherogenic properties of TG/HDL-C. It has been
reported that increase in TG/HDL-C is significantly as-
sociated with decrease in LDL particle size and increase
in fractional esterification rates of cholesterol in plasma
depleted of apoB-lipoproteins; hence the proposed name
for TG/HDL-C being atherogenic index of plasma [39].
In light of available evidence, including the results of our
study, it seems reasonable to conclude that TG/HDL-C
may serve as a useful marker to identify individuals at
increased risk of CVD.
Several limitations to our study should be considered.
This study is a cross-sectional design, thus longitudinal
studies are needed to explore whether the association
between TG/HDL-C and metabolic syndrome persists or
changes over time in men and women. Further, the
M-CHAT participants were recruited across a range of
BMI, so this study may not be representative of the
general population. However, recruiting people across
ranges of BMI allows for the opportunity to explore the
associations between lipid ratios and metabolic syndrome
in the population with a range of body sizes. Also, the re-
sults of our analyses indicate a significant association bet-
ween lipid ratios and number of metabolic syndrome
components independent of BMI. Moreover, our analyses
were adjusted for age, ethnicity, smoking, status, alcohol
consumption, physical activity, family history of CVD and
BMI (and menopausal status in women) but not for diet
known to influence plasma TG levels. Of importance, TG/
HDL-C cut-points for identifying individuals at risk may
vary across ethnicity and race [40,41]. Also, TG/HDL-C
was shown not to be a reliable risk marker in individuals
of South Asian [41] and African American origin [42,43].
While statistical power did not allow us to additionally
stratify our analyses by ethnicity, given the established
ethnic differences in the way body fat is accumulated
[44,45] and ethnic differences in cardiometabolic risk
[46,47], we believe that further research featuring ethnic-
specific analyses is warranted.
Conclusions
In conclusion, our study shows strong positive associ-
ation between lipid ratios and metabolic syndrome in
apparently healthy men and women (without CVD and
not on CVD-related medications) drawn from an eth-
nically diverse population. TG/HDL-C appeared to be a
superior marker compared to TC/HDL-C, LDL-C/HDL-C,
and nonHDL-C/HDL-C, and it is useful for identifying
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TG/HDL-C readings of 1.62 or greater in men and 1.18 or
greater in women can help primary care physicians easily
identify individuals at increased risk for CVD. Early identi-
fication of individuals at risk would allow for an early im-
plementation of lifestyle and medication strategies, while
TG/HDL-C could be further used to evaluate the success
of such strategies.
Methods
Apparently healthy men and women were recruited as
part of the Multi-Cultural Community Health Assessment
Trial (M-CHAT) designed to compare body fat distribu-
tion of Aboriginal, Chinese, and South Asian populations
to that of a European population and explore how fat
distribution relates to CVD risk factors [48]. Details on re-
cruitment of study participants have already been pub-
lished [48]. In brief, eligible participants were apparently
healthy individuals between ages of 30 and 65 of Aborigi-
nal, Chinese, European and South Asian origin residing in
the Vancouver mainland. To ensure a range of body fat
mass across groups, participants were recruited from the
following BMI (kg/m2) ranges: 18.5-24.9 (low range), 25.0-
29.9 (middle range), and 30 and over (upper range). Given
that it was challenging to identify Aboriginal men with a
BMI of less than 25, Aboriginal men of any BMI were re-
cruited. Similarly, due to a difficulty in identifying Chinese
individuals with a BMI of 30 kg/m2 and higher, the target
for the upper BMI range was changed to a BMI of 28 and
higher. Individuals with a fluctuation in weight that was
greater than 2.5 kg three months prior to the assessment
date, and those with diagnosed CVD or on medications to
treat CVD risk factors, were not eligible for the study.
Ethnicity was self-reported. All study participants pro-
vided informed consent for the study, and the study was
approved by the Simon Fraser University Research Ethics
Board.
All participants were assessed for socio-demographics
and risk factors. Following the standard protocols for
blood sample collection, shipment, and processing, fast-
ing blood samples were collected from each participant
at the research site and assessed for lipids and glucose at
St. Paul’s Hospital in Vancouver, Canada. Glucose, TC,
TG, and HDL-C were determined using standard proto-
cols by ADVIA 1650 analyzer (Bayer Health Care, LLC.,
New Jersey, USA). Friedwald formula was used to calcu-
late LDL-C [49]. Height and weight were measured, and
BMI was calculated as weight in kilograms divided by
height in metres squared. Waist circumference repre-
sented an average of two measurements taken upon ex-
piration at the mid point between the low rib margin
and iliac crest. Blood pressure was recorded as mean of
5 measurements taken after 10 minutes seated rest in
the left arm using BpTRU model BPM-200 oscillometricoffice blood pressure monitor (VSM MedTech Ltd.,
Coquitlam, British Columbia). Smoking status (current
smokers/non-smokers), alcohol consumption (currently
consume alcohol/do not consume alcohol) and family
history of CVD (yes/no) were determined by self-report.
Women self-reported their menopausal status by choos-
ing from the following options (women were provided a
definition for each of the options): pre-menopausal
(regular menstrual cycles), peri-menopausal (menopausal
transition with symptoms such as menstrual irregu-
larity), post-menopausal (end of menstrual cycles, at
least 12 months since the last menstrual period), or hys-
terectomy (surgical removal of the uterus). Menopausal
status variable used as a confounder in regression
analyses consisted of two categories, pre-menopausal
(pre-menopausal and peri-menopausal) and menopausal
(post-menopausal and hysterectomy). Physical activity
was measured using the Modifiable Physical Activity
questionnaire previously used in multi-ethnic popula-
tions and determined by self-report [50,51]. A person
would qualify as having metabolic syndrome if he/she
had three out of 5 risk factors present (hypertension,
hypertriglyceridaemia, lowered HDL-C, hyperglycaemia,
and central obesity) using the most recent harmonized
definition of the metabolic syndrome where ethnic spe-
cific thresholds for waist circumference were used [10].
Statistical analyses
Only participants with complete data for all metabolic syn-
drome components were included to the study (N = 797).
Considering significant sex differences in body fat distribu-
tion and cardiometablic risk [52-54], all statistical analyses
were performed separately for men and women. Cate-
gorical variables were presented as counts and percent-
ages, and differences between men and women were
explored using Chi-square test. Continuous variables were
presented as means ± standard deviation (SD) if normally
distributed, or medians with 25th and 75th percentiles if
not normally distributed. Differences between men and
women in the distribution of continuous variables were
explored using t-test and Mann U Whitney test for nor-
mally distributed and skewed data, respectively.
Age and ethnicity adjusted levels of lipid ratios across
the number of metabolic syndrome components were
determined using general linear modelling (Bonferroni-
corrected post hoc comparisons). In our apparently
healthy multiethnic study population, there was a limited
number of participants with 4 (n = 66) and 5 (n = 18)
metabolic syndrome components; therefore, we com-
bined these two categories. Poisson regression analysis
was used to explore the association between lipid ratios
and the number of metabolic syndrome components. All
models were adjusted for age, ethnicity, smoking, alcohol
consumption, physical activity, family history of CVD
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for menopausal status.
The clinical utility of lipid ratios to identify individuals
with metabolic syndrome was explored using receiver-
operating characteristic curve (ROC) analysis. Plots of
sensitivity (true positives) versus 1 minus specificity (false
positives) were constructed in both men and women for
each lipid ratio. Area under the curve (AUC) was calcu-
lated to explore which lipid ratio showed highest accuracy
in predicting metabolic syndrome. AUC is a measure of
discrimination, and AUC of 0.5, 0.6 ≤AUC< 7, 7 ≤AUC<
0.8, 0.8 ≤AUC< 0.9, and ≥ 0.9 corresponds to no discri-
mination, poor, acceptable, excellent, and outstanding
discrimination, respectively [23]. Optimal cut-off point of
each lipid ratio to identify individuals with metabolic syn-
drome corresponded to a maximum value of Youden
index that was calculated as sensitivity + specificity – 1
[55,56]. Additionally, the statistical significance of the dif-
ference between areas under the curves was tested using
the methods of De Long et al. [57]. Analyses were per-
formed using Statistical Package for Social Sciences (SPSS)
version 19 except for the comparisons of ROC curves that
were performed using MedCalc statistical software.
P values of less than 0.05 were considered statistically
significant.
Additional files
Additional file 1: Table S1. Mean levels (95% CI) of lipid ratios across
increasing number of metabolic syndrome components.
Additional file 2: Table S2. Partial correlations (age and ethnicity
adjusted) between lipid ratios and metabolic syndrome components in
men (A) and women (B).
Abbreviations
AUC: Area under the curve; BMI: Body mass index; CVD: Cardiovascular
disease; LDL-C/HDL-C: Low-density-lipoprotein-cholesterol-to-high-density-
lipoprotein-cholesterol; M-CHAT: Multi-Cultural Health Assessment Trial;
nonHDL-C/HDL-C: non-high-density-lipoprotein-cholesterol-to-high-density-
lipoprotein-cholesterol; ROC: Receiver-operating characteristic curve;




The authors declare that they have no competing interests.
Authors’ contribution
DG designed the study, performed statistical analyses and data interpretation
and wrote the manuscript. GBJM participated in the design of the study,
data interpretation, and helped draft the manuscript. JF critically assessed the
manuscript and participated in the study discussion. SAL participated in the
design of the study, data interpretation and study discussion. All authors
read and approved the final manuscript.
Author details
1Department of Biomedical Physiology and Kinesiology, Simon Fraser
University, 2600-515 West Hastings, Vancouver, British Columbia V6B 5K3,
Canada. 2Department of Pathology and Laboratory Medicine, University of
British Columbia, Vancouver, BC V6T 2B5, Canada. 3Division of Cardiology,
Providence Health Care, Healthy Heart Program, 1081 Burrard Street,Vancouver, BC V6Z 1Y6, Canada. 4Department of Medicine, University of
British Columbia, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9,
Canada. 5Faculty of Health Sciences, Simon Fraser University, Burnaby, British
Columbia V5A 1S6, Canada.
Received: 24 April 2014 Accepted: 28 September 2014
Published: 10 October 2014References
1. Ford ES, Li C, Sattar N: Metabolic syndrome and incident diabetes.
Diabetes Care 2008, 31(9):1898–1904.
2. Gupta AK, Prieto-Merino D, Dahlof B, Sever PS, Poulter NR, ASCOT Investigators:
Metabolic syndrome, impaired fasting glucose and obesity, as predictors
of incident diabetes in 14120 hypertensive patients of ASCOT-BPLA:
comparisons of their relative predictability using a novel approach.
Diabetic Medicine 2011, 28(8):941–947.
3. Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular
disease: a meta-analysis. Am J Med 2006, 119(10):812–819.
4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM:
Metabolic syndrome and risk of incident cardiovascular events and
death: a systematic review and meta-analysis of longitudinal studies.
JACC 2007, 49(4):403–414.
5. Mohan V, Deepa M: The metabolic syndrome in developing countries.
Diabetes Voice 2006, 51:15–17.
6. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic
syndrome among US adults. Diabetes Care 2004, 27:2444–2449.
7. International Diabetes Federation: The IDF consensus worldwide definition of
the metabolic syndrome. [https://www.idf.org/webdata/docs/
MetS_def_update2006.pdf]
8. Balkau B, Charles MA: Comment on the provisional report from the WHO
consultation. European Group for the Study of Insulin Resistance (EGIR).
Diabetes Medicine 1999, 16(5):442–443.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III): Third report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.
Circulation 2002, 106(25):3143.
10. Alberti KGMM, Eckel RH, Grundy SM, Grundy SM, Zimmet PZ, Cleeman JI,
Donato KA, Fruchart J-C, James PT, Loria CM, Smith SC Jr: Harmonizing the
metabolic syndrome. A joint interim statement of the International
Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis Society; and
International Association for the Study of Obesity. Circulation 2009,
120:1640–1645.
11. Gupta M, Singh N, Tsiqoulis M, Kaiij M, Hirjikaka S, Quan A, Teoh H, Verma S:
Perceptions of Canadian primary care physicians towards cardiovascular
risk assessment and lipid management. Can J Cardiology 2012,
28(1):14–19.
12. Cordero A, Laclaustra M, Leon M, Casasnovas JA, Grima A, Luengo E,
Ordonez B, Bergua C, Bes M, Pascual I, Alegria E, on behalf of the MESYAS
Registry Investigators: Comparison of serum lipid values in subjects with
and without the metabolic syndrome. Am J Cardiol 2008, 102:424–428.
13. Onat A, Can G, Kaya H, Hergenc G: “Atherogenic index of plasma” (log10
triglyceride/high-density lipoprotein-cholesterol) predicts high blood
pressure, diabetes, and vascular events. J Clin Lipid 2010, 4:89–98.
14. Kimm H, Lee SW, Lee HS, Shim KW, Cho CY, Yun JE, Jee SH: Associations
between lipid measures and metabolic syndrome, insulin resistance and
adiponectin. Circ J 2010, 74:931–937.
15. Kawamoto R, Tabara Y, Kohara K, Miki T, Takayama S, Abe M, Katoh T,
Ohtsuka N: Relationships between lipid profiles and metabolic syndrome,
insulin resistance and serum high molecular adiponectin in Japanese
community-dwelling adults. Lipids Health Dis 2011, 10:79.
16. Kim SW, Jee JH, Kim HJ, Jin SM, Suh S, Bae JC, Kim SW, Chung JH, Min YK,
Lee MS, Lee MK, Kim KW, Kim JH: Non-HDL-cholesterol/HDL-cholesterol is
a better predictor of metabolic syndrome and insulin resistance than
apolipoprotein B/apolipoprotein A1. Int J Cardiol 2013, 168:2678–2683.
17. Arthur FKN, Adu-Frimpong M, Osei-Yeboah J, Mensah FO, Owusu L:
Prediction of metabolic syndrome among postmenopausal Ghanian
Gasevic et al. Lipids in Health and Disease 2014, 13:159 Page 9 of 10
http://www.lipidworld.com/content/13/1/159women using obesity and atherogenic markers. Lipids Health Dis 2012,
11:101.
18. Wang TD, Chen WJ, Chien KL, She-Yi Su SS, Hsu HC, Chen MF, Liau CS, Lee
YT: Efficacy of cholesterol levels and ratios in predicting future coronary
heart disease in a Chinese population. Am J Cardiol 2001, 88(7):737–743.
19. Ingelsson E, Schaefer E, Contois JH, McNamara JR, Sullivan L, Keyes MJ,
Pencina MJ, Schoonmaker C, Wilson PWF, D’Agostino RB, Vasan RS: Clinical
utility of different lipid measures for prediction of coronary heart disease
in men and women. JAMA 2007, 298(7):776–785.
20. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J,
Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, for the
INTERHEART study investigators: Lipids, lipoproteins, and apolipoprteins as
risk markers of myocardial infarction in 52 countries (the INTERHEART
study): a case–control study. Lancet 2008, 372:224–233.
21. Eliasson B, Cederholm J, Eeq-Olofsson K, Svensson AM, Zethelius B,
Gudbjornsdottir S, on behalf of the National Diabetes Register: Clinical
usefulness of different lipid measures for prediction of coronary heart
disease in type 2 diabetes. Diabetes Care 2011, 34(9):2095–2100.
22. Klein BEK, Klein R, Lee KE: Components of the metabolic syndrome and
risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care
2002, 25(10):1790–1794.
23. Hosmer DW, Lemeshow S: Applied Logistic Regression. 2nd edition. Hoboken,
NJ: John Wiley & sons, Inc; 2000:156–164.
24. Salazar MR, Carbajal HA, Espeche WG, Aizpurua M, Sisnieguez CE, March CE,
Balbin E, Stavile RN, Reaven GM: Identifying cardiovascular disease risk
and outcome: use of the plasma triglyceride/high-density lipoprotein
cholesterol concentration ratio versus metabolic syndrome criteria.
J Intern Med 2013, 273:595–601.
25. Vega GL, Barlow CE, Grundy SM, Leonard D, DeFina LF: Triglyceride-to-
high-density-lipoprotein-cholesterol ratio is an index of heart disease
mortality and of incidence of type 2 diabetes mellitus in men. J Investig
Med 2014, 62:345–349.
26. Murquia-Romero M, Jimenez-Flores JR, Sinqrist-Flores SC, Espinoza-Camacho
MA, Jimenez-Morales M, Pina E, Mendez-Cruz AR, Villalobos-Molina R,
Reaven GM: Plasma triglyceride/HLD-cholesterol ratio, insulin resistance,
and cardiometabolic risk in young adults. J Lipid Res 2013, 54(10):2795–2799.
27. Stein E, Kushner H, Gidding S, Falkner B: Plasma lipid concentrations in
nondiabetic African American adults: association with insulin resistance
and the metabolic syndrome. Metabolism 2007, 56(7):954–960.
28. Karelis AD, Pasternyk SM, Messier L, St-Pierre DH, Lavoie JM, Garrel D,
Rabasa-Lhoret R: Relationship between insulin sensitivity and the
triglyceride-HDL-C ratio in overweight and obese postmenopausal
women: a MONET study. Appl Physiol Nutr Metab 2007, 32(6):1089–1096.
29. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J,
Krauss RM: Is there a simple way to identify insulin-resistant individuals
at increased risk of cardiovascular disease? Am J Cardiol 2005,
96(3):399–404.
30. Fan X, Liu EY, Hoffman VP, Potts AJ, Sharma B, Henderson DC: Triglyceride/
high-density lipoprotein cholesterol ratio: a surrogate to predict insulin
resistance and low-density lipoprotein particle size in nondiabetic
patients with schizophrenia. J Clin Psych 2011, 72(6):806–812.
31. Kang H-T, Yoon J-H, Kim J-Y, Ahn S-K, Kinton JA, Koh S-B, Kim J-K: The
association between the ratio of triglyceride to HDL-C and insulin
resistance according to waist circumference in rural Korean population.
Nutr Metab Cardiovasc Dis 2012, 22(12):1054–1060.
32. Haedegh F, Hatami M, Tohidi M, Sarbakhsh P, Saadat N, Azizi F: Lipid ratios
and appropriate cut off values for prediction of diabetes: a cohort of
Iranian men and women. Lipids Health Dis 2010, 9:85.
33. Zoppini G, Negri C, Stoico V, Casati S, Pichiri I, Bonora E: Triglyceride-high-
density lipoprotein cholesterol is associated with microvascular
complications in type 2 diabetes mellitus. Metabolism 2012, 61(1):22–29.
34. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Relation of high TG-low
HDL cholesterol and LDL cholesterol to the incidence of ischemic heart
disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler
Thromb Vasc Biol 1997, 17:1114–1120.
35. Hadaegh F, Khalili D, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F:
Triglyceride/HDL-cholesterol ratio is an independent predictor for
coronary heart disease in a population of Iranian men. Nutr Metab
Cardiov Dis 2009, 19(6):401–408.
36. Casella-Filho A, Hueb W, Jonke V, Santos R, Favarato D, Lima E, Segre A,
Cury Rezende P, Larossa Garzillo C, Chacra APM, Ramires J, Kalil-Filho R: Thetriglyceride/HDL ratio remains as an independent plasma lipid marker of
major cardiovascular events in diabetic patients 10-year follow-up from
the Medicine Angioplasty or Surgery Study II (MASS II). JACC 2012,
59(13s1):E1663–E1663 (abstract).
37. Salazar MR, Carbajal HA, Espeche WG, Aizpurua M, Maciel PM, Reaven GM:
Identification of cardiometabolic risk: visceral adiposity index versus
triglyceride/HDL cholesterol ratio. AM J Med 2014, 127:152–157.
38. Cordero A, Andres E, Ordonez B, Leon M, Laclaustra M, Grima A, Luengo E,
Moreno J, Bes M, Pascual I, Civeira F, Pocovi M, Alegria E, Casasnovas JA,
on behalf of the MESYAS (Metabolic Syndrome Active Subjects) Study
investigators: Usefulness of triglycerides-to-high-density lipoprotein
cholesterol ratio for predicting the first coronary event in men. Am J
Cardiol 2009, 104:1393–1397.
39. Dobiasova M, Frohlich J: The plasma parameter log (TG/HDL-C) as an
atherogenic index: correlation with lipoprotein particle size and
esterification rate inapoB-lipoprotein-depleted plasma (FERHDL).
Clin Biochem 2001, 34(7):583–588.
40. Li C, Ford ES, Menq YX, Mokdad AH, Reaven GM: Does the association of
the triglyceride to high-density lipoprotein ratio with fasting serum
insulin differ by race/ethnicity? Cardiovasc Diabetol 2008, 7:4.
41. Gasevic D, Frohlich J, Mancini GB, Lear SA: The association between
triglyceride to high-density-lipoprotein cholesterol ration and insulin
resistance in a multiethnic primary prevention cohort. Metabolism 2012,
61(4):583–589.
42. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC: Fasting
triglyceride and the triglyceride-HDL cholesterol ratio are not
markers of insulin resistance in African Americans. Arch Int Med 2005,
165(12):1395–1400.
43. Knight MG, Goedecke JH, Ricks M, Evans J, Levitt NS, Tulloch-Reid MK,
Sumner AE: The TG/HDL-C ratio does not predict insulin resistance in
overweight women of African descent: a study of south African, African
American, and west African women. Ethn Dis 2011, 21(4):490–494.
44. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham
CL: Visceral adipose tissue accumulation differs according to ethnic
background: results of the Multicultural Community Health Assessment
Trial (M-CHAT). Am J Clin Nutr 2007, 86(2):353–359.
45. Kohli S, Sniderman AD, Tchernof A, Lear SA: Ethnic-specific differences
in abdominal subcutaneous tissue compartments. Obesity 2010,
18(11):2177–2183.
46. Kurian AK, Cardarelli KM: Racial and ethnic differences in cardiovascular
disease risk factors: a systematic review. Ethn Dis 2007, 17(1):143–152.
47. Chiu M, Austin PC, Manuel DG, Tu JV: Comparison of cardiovascular risk
profiles among ethnic groups using population health surveys between
1996 and 2007. CMAJ 2010, 182(8):E301–E310.
48. Lear SA, Birmingham CL, Chockalingam A, Humphries KH: Study design of
the multicultural community health assessment trial (M-CHAT): A
comparison of body fat distribution in four distinct populations. Ethn Dis
2006, 16:96–100.
49. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 1972, 18:499–502.
50. Kriska AM, Knowler WC, LaPorte RE, Drash AL, Wing RR, Blair SN, Bennett PH,
Kuller LH: Development of questionnaire to examine relationship of
physical activity and diabetes in Pima Indians. Diabetes Care 1990,
13:401–411.
51. Pereira MA, Kriska AM, Joswiak ML, Dowse GK, Collins VR, Zimmet PZ,
Gareeboo H, Chitson P, Hemrai F, Purran A: Physical inactivity and glucose
intolerance in the multiethnic island of Mauritius. Med Sci Sports Exerc
1995, 27:1626–1634.
52. Larsson B, Bengtsson C, Bjorntorp P, Lapidus L, Sjostrom L, Syardsudd K,
Tibblin G, Wedel H, Welin L, Wilhelmsen L: Is abdominal body fat
distribution a major explanation for the sex difference in the incidence
of myocardial infarction? The study of men born in 1913 and the study
ow women, Goteborg. Sweden. Am J Epidemiology 1992, 135(3):266–273.
53. Freedman DS, Jacobsen SJ, Barboriak JJ, Sobocinski KA, Anderson AJ,
Kissebah AH, Sasse EA, Gruchow HW: Body fat distribution and male/
female differences in lipids and lipoproteins. Circulation 1990,
81:1498–1506.
54. He H, Ni Y, Chen J, Zhao Z, Zhong J, Liu D, Yan Z, Zhang W, Zhu Z: Sex
differences in cardiometabolic risk profile and adiponectin expression in
subjects with visceral obesity. Transl Res 2010, 155(2):71–77.
Gasevic et al. Lipids in Health and Disease 2014, 13:159 Page 10 of 10
http://www.lipidworld.com/content/13/1/15955. Youden WJ: Index for rating diagnostic tests. Cancer 1950, 3:32–35.
56. Schisterman EF, Perkins NJ, Liu A, Bondell H: Optimal cut-point and its
corresponding Youden Index to discriminate individuals using pooled
blood samples. Epidemiology 2005, 16:73–81.
57. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under
two or more correlated receiver operating characteristic curves:
a nonparametric approach. Biometrics 1988, 44:837–845.
doi:10.1186/1476-511X-13-159
Cite this article as: Gasevic et al.: Clinical usefulness of lipid ratios to
identify men and women with metabolic syndrome: a cross-sectional
study. Lipids in Health and Disease 2014 13:159.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
